Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) saw a large drop in short interest in the month of April. As of April 15th, there was short interest totalling 1,140,000 shares, a drop of 16.8% from the March 31st total of 1,370,000 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is presently ∞ days.
NASDAQ:EGRX traded down $0.72 during midday trading on Tuesday, reaching $41.25. 3,699 shares of the stock traded hands, compared to its average volume of 119,369. The stock has a market capitalization of $545.20 million, a P/E ratio of 118.32 and a beta of 0.74. The company has a debt-to-equity ratio of 0.16, a quick ratio of 3.45 and a current ratio of 3.60. The company has a fifty day moving average of $42.70 and a 200 day moving average of $46.08. Eagle Pharmaceuticals has a 12 month low of $36.48 and a 12 month high of $56.16.
Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its quarterly earnings data on Monday, March 1st. The specialty pharmaceutical company reported $0.96 EPS for the quarter, beating the consensus estimate of ($1.42) by $2.38. Eagle Pharmaceuticals had a net margin of 2.65% and a return on equity of 8.50%. The firm had revenue of $49.92 million during the quarter, compared to the consensus estimate of $50.08 million. On average, analysts predict that Eagle Pharmaceuticals will post -1.07 EPS for the current fiscal year.
Separately, Zacks Investment Research raised Eagle Pharmaceuticals from a “sell” rating to a “buy” rating and set a $48.00 target price for the company in a research note on Monday, March 8th.
About Eagle Pharmaceuticals
Eagle Pharmaceuticals, Inc, a biotechnology pharmaceutical company, focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.
Read More: Balance Sheet
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.